CLOs on the Move


 
Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.janpixbio.com
  • One Broadway, 14th Floor
    Cambridge, MA USA 02142
  • Phone: 617.956.2803

Executives

Name Title Contact Details

Similar Companies

Boston Immune Technologies and Therapeutics

Boston Immune Technologies & Therapeutics based Inc

Second Genome

Second Genome is a clinical stage company with a mission to improve human health by unlocking the full potential of the microbiome. We offer the most robust approach to microbiome drug discovery and development through the deepest understanding of how the microbiome works in human health.

Axsome

Axsome Therapeutics is a biopharmaceutical company developing novel therapies for the treatment of CNS disorders. Axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. The company is based in New York City.

Horizon Discovery

Horizon builds human disease models and reagents derived from genetically-engineered cells that its customers use, or that are deployed on their behalf to: gain knowledge of the genetic drivers of disease; develop novel drugs or cell therapies targeted...

Linden Labs

Linden Labs is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.